Fan Jin
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)Ministry of Education of the People's Republic of China(CN)Wenzhou University(CN)Guizhou Normal University(CN)Wenzhou Medical University(CN)Wenzhou Municipal Sci-Tech Bureau(CN)Ministry of Education(TH)Women's Hospital, School of Medicine, Zhejiang University(CN)Wenzhou City People's Hospital(CN)Oil and Gas Center(CN)Zhejiang University(CN)China National Petroleum Corporation (China)(CN)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Genetic factors in colorectal cancer, Cancer Genomics and Diagnostics, Epigenetics and DNA Methylation, Endometrial and Cervical Cancer Treatments
Most-Cited Works
- → Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study(2019)3,087 cited
- → Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study(2020)2,424 cited
- → Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial(2015)1,372 cited
- → Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study(2022)470 cited
- → Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study(2022)415 cited